PMC:7200337 / 88294-89513
Annnotations
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32505227-17537853-46575405 | 395-399 | 17537853 | denotes | 2007 |
32505227-31925415-46575406 | 545-549 | 31925415 | denotes | 2020 |
32505227-31924756-46575407 | 675-679 | 31924756 | denotes | 2020 |
32505227-26867177-46575408 | 1105-1109 | 26867177 | denotes | 2016 |
32505227-16482545-46575409 | 1130-1134 | 16482545 | denotes | 2006 |
T67437 | 395-399 | 17537853 | denotes | 2007 |
T59534 | 545-549 | 31925415 | denotes | 2020 |
T50703 | 675-679 | 31924756 | denotes | 2020 |
T33795 | 1105-1109 | 26867177 | denotes | 2016 |
T23514 | 1130-1134 | 16482545 | denotes | 2006 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T502 | 122-130 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T503 | 236-246 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
T504 | 278-286 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T505 | 289-298 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T506 | 520-529 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T507 | 815-823 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T508 | 837-845 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T509 | 891-899 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T938 | 16-19 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T939 | 25-26 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T940 | 587-588 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T941 | 697-698 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T942 | 768-777 | http://purl.obolibrary.org/obo/SO_0000418 | denotes | signaling |
T943 | 1047-1054 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | viruses |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T276 | 484-493 | Chemical | denotes | ribavirin | http://purl.obolibrary.org/obo/CHEBI_63580 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T200 | 131-143 | http://purl.obolibrary.org/obo/GO_0009405 | denotes | pathogenesis |
T201 | 768-777 | http://purl.obolibrary.org/obo/GO_0023052 | denotes | signaling |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
2902 | 1147-1156 | Gene | denotes | IFN-I/III | |
2903 | 1026-1028 | Gene | denotes | to | Gene:6999 |
2904 | 981-983 | Gene | denotes | to | Gene:6999 |
2905 | 872-874 | Gene | denotes | to | Gene:6999 |
2906 | 812-814 | Gene | denotes | to | Gene:6999 |
2907 | 111-113 | Gene | denotes | to | Gene:6999 |
2908 | 220-235 | Species | denotes | betacoronavirus | Tax:694002 |
2909 | 264-272 | Species | denotes | patients | Tax:9606 |
2910 | 497-505 | Species | denotes | patients | Tax:9606 |
2911 | 815-825 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
2912 | 837-847 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
2913 | 891-899 | Species | denotes | SARS-CoV | Tax:694009 |
2914 | 984-1001 | Species | denotes | betacoronaviruses | Tax:694002 |
2915 | 484-493 | Chemical | denotes | ribavirin | MESH:D012254 |
2916 | 122-130 | Disease | denotes | COVID-19 | MESH:C000657245 |
2917 | 236-246 | Disease | denotes | infections | MESH:D007239 |
2918 | 278-298 | Disease | denotes | SARS-CoV-1 infection | MESH:C000657245 |
2919 | 511-529 | Disease | denotes | MERS-CoV infection | MESH:D018352 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T505 | 0-144 | Sentence | denotes | Recently, there has been a growing interest in the potential therapeutic impact of modulating the IFN response to disable COVID-19 pathogenesis. |
T506 | 145-247 | Sentence | denotes | Before the current pandemic, groups have studied the role of IFNs in other betacoronavirus infections. |
T507 | 248-401 | Sentence | denotes | One study of 40 patients with SARS-CoV-1 infection described unresolved elevated type I IFNs and ISGs in those with poor outcomes (Cameron et al., 2007). |
T508 | 402-681 | Sentence | denotes | Others report that exogenous type I IFN does not improve outcomes when given with ribavirin in patients with MERS-CoV infection (Arabi et al., 2020), suggesting that the role of IFN as a therapeutic or prophylactic option may be strain or species specific (Sheahan et al., 2020). |
T509 | 682-932 | Sentence | denotes | Interestingly, a recent study by Mount Sinai virology groups revealed that type I IFN signaling is impaired in the early response to SARS-CoV-2; in vitro, SARS-CoV-2 may be more susceptible to type I IFN than SARS-CoV-1 is (Blanco-Melo et al., 2020). |
T510 | 933-1219 | Sentence | denotes | Based on additional evidence that IFN responses to betacoronaviruses are altered as compared to other respiratory viruses (Blanco-Melo et al., 2020, Channappanavar et al., 2016, Okabayashi et al., 2006), trials of IFN-I/III administration have been initiated (NCT04343976, NCT04331899). |